5 ESSENTIAL ELEMENTS FOR ABBV-744 DRUG DEVELOPMENT PROGRESS AND TIMELINE

In Section C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment right until ailment progression or the individuals are unable to tolerate the study drugs.Feasible new approaches with the prognosis and treatment of AML. (A) The identification of super enh